Themis raises €7M, adds GSK vet to board as partnership plans gather pace

Themis Bioscience has raised €7 million ($7.8 million) and reshaped its board of directors as it prepares to start mid-phase trials and step up its partnership strategy. Wellington Partners led the round, which gives Themis the money to move its Chikungunya vaccine candidate into Phase II.

Source: www.fiercebiotech.com

---